What maintenance strategy would you consider for a patient like this?
So assuming that the patient received three agents and two of those were pemetrexed and bevacizumab, my recommendation would be to continue both pemetrexed and bevacizumab after the initial cycles. To me, maintenance therapy is a true no-brainer. At the end of your induction, however you define it, whatever drugs you choose, you then make an assessment, did these drugs help the patient. And you could answer that yes or no using objective and subjective criteria of your own. You then can ask is this drug safe at this point. And the third question is does this drug make sense to the patient who’s receiving it, and at the end of induction, you ask those three questions, and if the answer to all those things are that it’s effective, it’s safe, and the patient feels it’s helped them and makes sense for them and where they are in their lives, those drugs should be discontinued(?). And, in the case of this patient, it would be continuing both pemetrexed and bevacizumab.
mNSCLC: Case 1
RP is a 72 year old whose past medical history is notable for hypertension (well-controlled), hyperuricemia, and gout. He presents to his PCP with fatigue, progressive dyspnea, and a persistent, nonproductive cough of approximately 1 month’s duration. He is a former smoker and quit approximately 30 years ago.
Chest X-ray in October 2015 showed a large mass in the upper left lobe and CT scan showed a left pleural effusion and enlargement of the left mediastinal and hilar lymph node.
MRI of the brain was negative for intracranial metastases.
The patient underwent resection of the primary mass which showed large cell carcinoma. Pleural fluid was tapped and also positive.
His lung cancer was staged as 4. His biopsy was sent for molecular testing and showed no actionable mutations in EGFR or ALK.
His current performance status is 1.
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More